



Dawson James Securities Announces the Completion of Public Offering for Biocept, Inc. for Approximate Gross Proceeds of \$3,349,636 million

Boca Raton, FL, December 7, 2017-- Dawson James Securities, Inc. in conjunction with Biocept, Inc. (NASDAQ: BIOC) announced the closing today of a public offering of 4,925,936 shares of the Company's common stock priced at \$.68 per share which was the closing price of the Company's common stock on The NASDAQ Capital Market on December 4, 2017. No warrants to purchase shares of the Company's common stock were issued to the investors in connection with the offering.

Dawson James Securities, Inc. acted as the sole manager for the offering. Gross proceeds from the transaction to Biocept are approximately \$3,349,636 million. Biocept Inc. intends to use the net proceeds for working capital and general corporate purposes

The shares described above were offered by Biocept, Inc. pursuant to a registration statement previously filed with, and subsequently declared effective by the Securities and Exchange Commission ("SEC") on May 21, 2015.. A final prospectus supplement relating to the offering was filed with the SEC and is available, along with the accompanying base prospectus, on the SEC's website at <http://www.sec.gov>, or by contacting Dawson James: 1 N. Federal Hwy; Suite 500, Boca Raton, FL 33432 ATTN: Prospectus Department.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

About Dawson James Securities

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors



and is a full service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, Maryland and New Jersey. www.dawsonjames.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Member FINRA/SIPC. For more information, please contact:

Elise Stern, Managing Director, Head of Capital Markets

estern@dawsonjames.com

561-208-2926